deter fs 250 flydende bejdse
bayer a/s - clothianidin - flydende bejdse - 250 g/l clothianidin
gaucho ws 70 (reg.nr. 18-650) vanddispergerbart pulver til bejdsning i opslemning
bayer a/s - imidacloprid - vanddispergerbart pulver til bejdsning i opslemning - 700 g/kg imidacloprid
zeppelin granulat
bayer a/s - glyphosat, diflufenican - granulat - 160 g/kg glyphosat ; 40 g/kg diflufenican
betanal classic flydende middel
bayer a/s - phenmedipham - flydende middel - 160 g/l phenmedipham
previcur n flydende middel
bayer a/s - propamocarb - flydende middel - 640 g/l propamocarb
keeper l mod ukrudt suspensionskoncentrat
bayer a/s - glyphosat, diflufenican - suspensionskoncentrat - 250 g/l glyphosat ; 40 g/l diflufenican
keeper spray vandopløseligt koncentrat
bayer a/s - glyphosat - vandopløseligt koncentrat - 7,2 g/l glyphosat
keeper mod ukrudt koncentrat flydende middel
bayer a/s - glyphosat - flydende middel - 120 g/l glyphosat
contans vanddispergerbart granulat
bayer a/s - coniothyrium - vanddispergerbart granulat - 1000000000000 cfu/kg coniothyrium minitans
adempas
bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.